Quarterly ResultApr 29, 2026, 04:05 PM
PRCT Q1 Revenue +20% to $83.1M; U.S. Procedures +30%; FDA Clearance
AI Summary
PROCEPT BioRobotics Corp reported strong unaudited financial results for Q1 2026, with total revenue increasing 20% to $83.1 million and U.S. procedures growing 30% to approximately 12,200. The company also achieved a gross margin of 65% and reaffirmed its full-year 2026 revenue guidance of $390 million to $410 million. Despite an increased net loss of $31.6 million due to continued investments, the company highlighted operational improvements and received FDA clearance for its second-generation FirstAssist AI™ software.
Key Highlights
- Q1 2026 total revenue: $83.1M, an increase of 20% compared to prior year.
- Q1 2026 U.S. procedures: approximately 12,200, an increase of 30% YoY.
- Gross margin for Q1 2026: 65%, up from 64% in the prior year period.
- Net loss for Q1 2026: $31.6M, compared to a loss of $24.7M in prior year.
- Received FDA clearance for second-generation FirstAssist AI™ software.
- Full-year 2026 revenue guidance reaffirmed: $390M to $410M.
- U.S. install base as of March 31, 2026: 765 systems, a 40% increase YoY.